NCT00757809

Brief Summary

Study to investigate the occurence of diarrhea after either once daily or twice daily dosing for 14 days.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Oct 2008

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 23, 2008

Completed
8 days until next milestone

Study Start

First participant enrolled

October 1, 2008

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2008

Completed
Last Updated

May 14, 2012

Status Verified

May 1, 2012

Enrollment Period

Same day

First QC Date

September 19, 2008

Last Update Submit

May 10, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Occurence of diarrhea

    14 days

Study Arms (2)

QD

EXPERIMENTAL

Once daily

Drug: neratinib

BID

EXPERIMENTAL

Twice daily

Drug: neratinib

Interventions

HKI-272

BIDQD

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy male and female (non-child bearing potential) subjects
  • Ages 18-50.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Unknown Facility

Austin, Texas, 78752, United States

Location

Unknown Facility

Tacoma, Washington, 98418, United States

Location

MeSH Terms

Interventions

neratinib

Study Officials

  • Puma

    Biotechnology

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 19, 2008

First Posted

September 23, 2008

Study Start

October 1, 2008

Primary Completion

October 1, 2008

Study Completion

October 1, 2008

Last Updated

May 14, 2012

Record last verified: 2012-05

Locations